Sara Lonardi, MD, discusses the final OS analysis of #CheckMate8HW from #ESMO26 and why nivolumab/ipilimumab should be offered to nearly all patients with MSI-H/dMMR mCRC. Read the full interview from Targeted Onc: www.targetedonc.com/view/lonardi...

#ESMOGI25 | Dr. Elena Elez shares insights with @ecancer.org on the #CheckMate8HW trial 🔬

Watch the video here 👇

🗞️ Recently published in NEJM, the phase 3 open-label #CheckMate8HW results demonstrate that first-line immunotherapy combination improves outcomes in patients with metastatic #ColorectalCancer versus chemotherapy

➡️ https://linke.to/Checkmate8HWNEJMVHIO

ESMO GI 2025 Highlights: CheckMate 8HW Trial on HRQoL in MSI-H/dMMR mCRC with NIVO + IPI
@myesmo.bsky.social

oncodaily.com/oncolibrary/...

#OncoDaily #Oncology #Cancer #Health #Medicine #MedEd #MedOnc #MedNews #ESMO #ESMOGI25 #CheckMate8HW #mCRC #ColorectalCancer

How will the CheckMate 8HW trial impact the treatment of metastatic colorectal cancer (MSI-H/dMMR)? Dr. Christopher Lieu breaks it down in this Clinic Conversation of the Week.

Read the full interview: www.youtube.com/watch?v=j2Hm...

#ClinicConversation #CheckMate8HW #ColorectalCancer

5. #Checkmate8HW: Ph 3, dMMR/MSI-H unresectable or mCRC, Ipi (1mg/kg) + Nivo (240mg) Q3W for 4 cycles and then Nivo alone vs Nivo:

- mPFS NR for Ipi/Nivo vs 39·3 months
- ORR: 71% vs 58%
- Any grade AEs 81% from Ipi/Nivo vs 71% Nivo alone. 3 Rx related deaths.

6/8

Happened this week: @FDA approves Nivo/Ipi vs. Nivo alone for #MSIhigh or #dMMR met #colorectal #cancer #Checkmate8HW
☑️Median PFS was NR in the combo arm vs. 39.3M (HR = 0.62 [95% CI: 0.48, 0.81]
☑️ORR = 71% vs. 58% (p-value 0.0011)
#CancerResearch #immunotherapy @bristolmyerssquibb.bsky.social

🎧 Stay informed and join the conversation! #ColorectalCancer #Immunotherapy #MSIH #dMMR #FDAapproval #Oncology #CheckMate8HW #MedicalInnovation #FDA #Nivolumab #Ipilimumab
open.spotify.com/show/6yKyfXw...